Aspira Women’s Health Inc. (NASDAQ:AWH) Short Interest Down 18.6% in December

Aspira Women’s Health Inc. (NASDAQ:AWH) was the recipient of a large decline in short interest during the month of December. As of December 31st, there was short interest totalling 356,900 shares, a decline of 18.6% from the December 15th total of 438,500 shares. Based on an average daily trading volume, of 100,900 shares, the short-interest ratio is presently 3.5 days. Approximately 2.9% of the company’s stock are sold short.

Analyst Ratings Changes

Separately, StockNews.com began coverage on Aspira Women’s Health in a report on Sunday, January 12th. They issued a “hold” rating for the company.

Aspira Women’s Health Trading Down 3.1 %

Shares of Aspira Women’s Health stock traded down $0.02 on Friday, reaching $0.50. 65,362 shares of the company were exchanged, compared to its average volume of 78,759. The company has a market capitalization of $8.34 million, a price-to-earnings ratio of -0.42 and a beta of 1.42. Aspira Women’s Health has a one year low of $0.38 and a one year high of $5.65. The company has a 50-day moving average of $0.74 and a 200 day moving average of $0.93.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Aspira Women’s Health stock. B. Riley Wealth Advisors Inc. increased its holdings in shares of Aspira Women’s Health Inc. (NASDAQ:AWH) by 88.6% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 236,396 shares of the company’s stock after acquiring an additional 111,022 shares during the quarter. B. Riley Wealth Advisors Inc. owned about 1.90% of Aspira Women’s Health worth $352,000 as of its most recent SEC filing. 12.19% of the stock is currently owned by hedge funds and other institutional investors.

Aspira Women’s Health Company Profile

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.